Callewaert L, Verrijdt G, Haelens A, Claessens F
Division of Biochemistry, Faculty of Medicine, University of Leuven, Leuven, Belgium.
Mol Endocrinol. 2004 Jun;18(6):1438-49. doi: 10.1210/me.2003-0313. Epub 2004 Mar 18.
The androgen receptor (AR) can be small ubiquitin-like modifier (SUMO)-ylated in its amino-terminal domain at lysines 385 and 511. This SUMO-ylation is responsive to several agonists, but is not induced by the pure antagonist hydroxyflutamide. We show that the main site of interaction of Ubc9, the SUMO-1 conjugating enzyme, resides in transcription activation unit 5. Overexpression of SUMO-1 represses the AR-mediated transcription, and this effect is abolished after mutating both SUMO-1 acceptor sites. On the other hand, the mutation of lysine 385 clearly affects the cooperativity of the receptor on multiple hormone response elements. Lysine 511 is not implicated in this function. Surprisingly, these effects on cooperativity clearly depend on the nature of the response elements. When selective androgen response elements, which are organized as direct repeats of 5'-TGTTCT-3'-like sequences, were tested, the lysine 385 mutation did not increase the androgen response. Point mutations changing the direct-repeat elements into inverted-repeat elements restored the effects of the lysine 385 mutation on cooperativity. In conclusion, SUMO-ylation of the AR might have a differential function in the control of cooperativity, depending on the conformation of the AR dimer bound to DNA.
雄激素受体(AR)可在其氨基末端结构域的赖氨酸385和511处发生小泛素样修饰物(SUMO)化。这种SUMO化对多种激动剂有反应,但不会被纯拮抗剂羟基氟他胺诱导。我们发现,SUMO-1缀合酶Ubc9的主要相互作用位点位于转录激活单元5。SUMO-1的过表达会抑制AR介导的转录,并且在突变两个SUMO-1受体位点后这种效应会被消除。另一方面,赖氨酸385的突变明显影响受体在多个激素反应元件上的协同性。赖氨酸511与该功能无关。令人惊讶的是,这些对协同性的影响明显取决于反应元件的性质。当测试由5'-TGTTCT-3'-样序列的直接重复组成的选择性雄激素反应元件时,赖氨酸385突变并未增加雄激素反应。将直接重复元件改变为反向重复元件的点突变恢复了赖氨酸385突变对协同性的影响。总之,AR的SUMO化在协同性控制中可能具有不同的功能,这取决于与DNA结合的AR二聚体的构象。